Literature DB >> 27428579

Is HIV still a special population for the treatment of hepatitis C?

Edward Cachay1, Vicente Soriano.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27428579      PMCID： PMC4955702          DOI： 10.1097/QAD.0000000000001135

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  15 in total

1.  Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.

Authors:  Colette Smith; Caroline A Sabin; Jens D Lundgren; Rodolphe Thiebaut; Rainer Weber; Matthew Law; Antonella d'Arminio Monforte; Ole Kirk; Nina Friis-Moller; Andrew Phillips; Peter Reiss; Wafaa El Sadr; Christian Pradier; Signe W Worm
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  Bradyarrhythmias Associated with Sofosbuvir Treatment.

Authors:  Hélène Fontaine; Arnaud Lazarus; Stanislas Pol; Caroline Pecriaux; François Bagate; Philippe Sultanik; Estelle Boueyre; Marion Corouge; Vincent Mallet; Anaïs Vallet-Pichard; Philippe Sogni; Denis Duboc
Journal:  N Engl J Med       Date:  2015-11-05       Impact factor: 91.245

3.  Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.

Authors:  Sandra Franco; Cristina Tural; Maria Nevot; José Moltó; Jürgen Kurt Rockstroh; Bonaventura Clotet; Miguel Angel Martinez
Journal:  Gastroenterology       Date:  2014-05-21       Impact factor: 22.682

4.  Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.

Authors:  Anne De Monte; Johan Courjon; Rodolphe Anty; Eric Cua; Alissa Naqvi; Véronique Mondain; Jacqueline Cottalorda; Laurence Ollier; Valérie Giordanengo
Journal:  J Clin Virol       Date:  2016-03-03       Impact factor: 3.168

5.  Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.

Authors:  Ana Arias; Antonio Aguilera; Vicente Soriano; Laura Benítez-Gutiérrez; Gemma Lledó; Daniel Navarro; Ana Treviño; Esteban Otero; José M Peña; Valentín Cuervas-Mons; Carmen de Mendoza
Journal:  Antivir Ther       Date:  2016-06-24

6.  New hepatitis C therapies for special patient populations.

Authors:  Vincent Soriano; Pablo Labarga; Carmen de Mendoza; José V Fernández-Montero; Isabella Esposito; Laura Benítez-Gutiérrez; José M Peña; Pablo Barreiro
Journal:  Expert Opin Pharmacother       Date:  2015-11-23       Impact factor: 3.889

Review 7.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.

Authors:  Lucy Platt; Philippa Easterbrook; Erin Gower; Bethan McDonald; Keith Sabin; Catherine McGowan; Irini Yanny; Homie Razavi; Peter Vickerman
Journal:  Lancet Infect Dis       Date:  2016-02-25       Impact factor: 25.071

8.  Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.

Authors:  D Grint; L Peters; C Schwarze-Zander; M Beniowski; C Pradier; M Battegay; D Jevtovic; V Soriano; J D Lundgren; J K Rockstroh; O Kirk; A Mocroft
Journal:  HIV Med       Date:  2013-07-19       Impact factor: 3.180

9.  The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care.

Authors:  Edward R Cachay; Lucas Hill; David Wyles; Bradford Colwell; Craig Ballard; Francesca Torriani; William C Mathews
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

10.  How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?

Authors:  Sahar Saeed; Erin C Strumpf; Sharon L Walmsley; Kathleen Rollet-Kurhajec; Neora Pick; Valerie Martel-Laferrière; Mark Hull; M John Gill; Joseph Cox; Curtis Cooper; Marina B Klein; Jeff Cohen; Brian Conway; Curtis Cooper; Pierre Côté; Joseph Cox; John Gill; Shariq Haider; Marianne Harris; David Haase; Mark Hull; Julio Montaner; Erica Moodie; Neora Pick; Anita Rachlis; Danielle Rouleau; Roger Sandre; Joseph Mark Tyndall; Marie-Louise Vachon; Sharon Walmsley; David Wong
Journal:  Clin Infect Dis       Date:  2016-01-06       Impact factor: 9.079
View more
  3 in total

1.  Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment.

Authors:  Edward R Cachay; Craig Ballard; Bradford Colwell; Francesca Torriani; Charles Hicks; Wm Christopher Mathews
Journal:  AIDS Res Ther       Date:  2017-09-20       Impact factor: 2.250

2.  Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.

Authors:  Cristina Aurora São Pedro Soeiro; Celina Andreia Melo Gonçalves; Marta Sofia Correia Marques; Maria Josefina Vazquez Méndez; Ana Paula Ribeiro Almeida Tavares; Ana Maria Lacerda Morgado Fernandes de Carvalho de Aboim Horta; Rui Manuel do Rosário Sarmento-Castro
Journal:  BMC Infect Dis       Date:  2018-08-03       Impact factor: 3.090

3.  Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study.

Authors:  Soraia M Machado; Aline G Vigani; Andrea G Leite; Ana Claudia M Diaz; Paulo Roberto A Ferreira; Dimas Carnaúba-Júnior; Simone B Tenore; Carlos Eduardo Brandão-Mello; Mario P Gonzalez; Fabiana Siroma; Kleber D Prado; Delzi V Nunes; Gaspar Lisboa-Neto; João Renato R Pinho; Fernanda M Malta; Raymundo S Azevedo; Steven S Witkin; Maria Cássia Mendes-Correa
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.